MX2021015336A - Dosificacion modificada de tocilizumab subcutaneo para la artritis reumatoide. - Google Patents

Dosificacion modificada de tocilizumab subcutaneo para la artritis reumatoide.

Info

Publication number
MX2021015336A
MX2021015336A MX2021015336A MX2021015336A MX2021015336A MX 2021015336 A MX2021015336 A MX 2021015336A MX 2021015336 A MX2021015336 A MX 2021015336A MX 2021015336 A MX2021015336 A MX 2021015336A MX 2021015336 A MX2021015336 A MX 2021015336A
Authority
MX
Mexico
Prior art keywords
rheumatoid arthritis
tocilizumab
subcutaneous
modified dosage
dosage
Prior art date
Application number
MX2021015336A
Other languages
English (en)
Spanish (es)
Inventor
Wenhui Wei
Chen Chieh- I
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021015336A publication Critical patent/MX2021015336A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021015336A 2019-06-12 2020-06-11 Dosificacion modificada de tocilizumab subcutaneo para la artritis reumatoide. MX2021015336A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962860611P 2019-06-12 2019-06-12
EP20305192 2020-02-27
PCT/US2020/037325 WO2020252214A1 (en) 2019-06-12 2020-06-11 Modified dosage of subcutaneous tocilizumab for rheumatoid arthritis

Publications (1)

Publication Number Publication Date
MX2021015336A true MX2021015336A (es) 2022-10-21

Family

ID=71170831

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015336A MX2021015336A (es) 2019-06-12 2020-06-11 Dosificacion modificada de tocilizumab subcutaneo para la artritis reumatoide.

Country Status (13)

Country Link
US (1) US20220242959A1 (https=)
EP (1) EP3983071A1 (https=)
JP (2) JP2022536739A (https=)
KR (1) KR20230047944A (https=)
CN (1) CN115003382A (https=)
AU (1) AU2020290484A1 (https=)
BR (1) BR112021025060A2 (https=)
CA (1) CA3143261A1 (https=)
CO (1) CO2022000064A2 (https=)
IL (1) IL288690A (https=)
MA (1) MA56190A (https=)
MX (1) MX2021015336A (https=)
WO (1) WO2020252214A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
CN115825415B (zh) * 2022-09-28 2023-07-14 珠海重链生物科技有限公司 阻断剂和体外免疫诊断产品、应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
KR20190120439A (ko) * 2010-11-08 2019-10-23 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체

Also Published As

Publication number Publication date
BR112021025060A2 (pt) 2022-02-22
JP2026032195A (ja) 2026-02-25
JP2022536739A (ja) 2022-08-18
WO2020252214A1 (en) 2020-12-17
IL288690A (en) 2022-02-01
KR20230047944A (ko) 2023-04-10
CN115003382A (zh) 2022-09-02
CA3143261A1 (en) 2020-12-17
CO2022000064A2 (es) 2022-04-08
US20220242959A1 (en) 2022-08-04
EP3983071A1 (en) 2022-04-20
MA56190A (fr) 2022-04-20
AU2020290484A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
PH12020552232A1 (en) IL-11 Antibodies
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
PH12020552229A1 (en) Il-11ra antibodies
MY189536A (en) Subcutaneous her2 antibody formulations
MX2018013762A (es) Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso.
ZA202005388B (en) Methods of treating ulcerative colitis
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
MX2021015336A (es) Dosificacion modificada de tocilizumab subcutaneo para la artritis reumatoide.
EA201892190A1 (ru) Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
ZA201907135B (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
MA44645B1 (fr) Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2
MX2025003476A (es) Anticuerpos anti-il-27 y usos de los mismos
PH12021552135A1 (en) Methods of treating al amyloidosis
PH12021551494A1 (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2021010119A (es) Tratamiento combinado con anticuerpos anti-cd39 y anticuerpos anti-pd1 o anti-pd-l1.
PH12023550178A1 (en) Anti-abeta antibodies
EA201992431A1 (ru) Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса
PH12021552536A1 (en) Methods for treatment of subjects with psoriatic arthritis